Publications Jose Baselga 2013-8 by chronological order.
Color code:
Publications where I disclosed
Publications that represented basic laboratory or translational work
Publications where disclosures are debatable. Most of them concerned exploratory
biomarkers or reporting the results of early clinical trials with experimental agents for
which a decision had been reached at the time of publication to not develop further.
These publications had no clinical nor financial implications.
Publications to be disclosed
1. Villarreal L, Méndez O, Salvans C, Gregori J, Baselga J, Villanueva J. “Unconventional secretion is
a major contributor of cancer cell line secretomes.” Mol Cell Proteomics. 2013 May;12(5):1046-60.
doi: 10.1074/mcp.M112.021618. PubMed PMID: 23268930; PubMed Central PMCID:
PMC3650320. BASIC SCIENCE.
2. Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM,
Piccart MJ, Sotiriou C. “PIK3CA genotype and a PIK3CA mutation-related gene signature and
response to everolimus and letrozole in estrogen receptor positive breast cancer.” PLoS One.
2013;8(1):e53292. doi: 10.1371/journal.pone.0053292. PubMed PMID: 23301057; PubMed Central
PMCID: PMC3534682 Translational.
3. Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario
R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J,
Villanueva J, Arribas J. “Constitutive HER2 signaling promotes breast cancer metastasis through
cellular senescence.” Cancer Res. 2013 Jan 1;73(1):450-8. doi: 10.1158/0008-5472.CAN-12-2301.
Erratum in: Cancer Res. 2013 Oct 1;73(19):6095. PubMed PMID: 23288917.
4. Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G,
Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA,
Piccart-Gebhart M. “Analysis of regional timelines to set up a global phase III clinical trial in breast
cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.” Oncologist.
2013;18(2):134-40. doi: 10.1634/theoncologist.2012-0342. PubMed PMID: 23359433; PubMed
Central PMCID: PMC3579596.
5. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN,
Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy
S, Toner M, Haber DA, Maheswaran S. “Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition.” Science. 2013; 339(6119):580-4. Epub 2013/02/02.
PMID: 23372014. BASIC SCIENCE.
6. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H,
Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D,
Campone M, Pritchard KI. “Effect of everolimus on bone marker levels and progressive disease in

 bone in BOLERO-2.” J Natl Cancer Inst. 2013 May 1;105(9):654-63. doi: 10.1093/jnci/djt026.
PubMed PMID: 23425564.
7. Zardavas D, Baselga J, Piccart M. “Emerging targeted agents in metastatic breast cancer.”
Nat
Rev Clin Oncol. 2013 Apr;10(4):191-210. doi: 10.1038/nrclinonc.2013.29. Review. PubMed PMID:
23459626.
8. Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G,
Baselga J. “Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with
HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebocontrolled phase III study.” Oncologist. 2013;18(3):257-64. doi: 10.1634/theoncologist.2012-0448.
PubMed PMID: 23475636; PubMed Central PMCID: PMC3607520.
9. Sandra M Swain, Sung-Bae Kim, Javier Cortés, Jungsil Ro, Vladimir Semiglazov, Mario Campone,
Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiss, Adam Knott, Emma Clark, Graham Ross,
Mark C Benyunes, José Baselga. Pertuzumab, trastuzumab, and docetaxel for HER2-positive
metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, doubleblind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461–71 YES
10. Soria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA,
Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS.
“Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase
inhibitor, in patients with advanced or metastatic solid tumours.” Eur J Cancer. 2013
May;49(8):1815-24. doi: 10.1016/j.ejca.2013.02.012. PubMed PMID: 23490650. I was not
consulting for BMS, study agent was not further developed
11. Burris HA 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K,
Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF,
Bauly H, Taran T, Sahmoud T, Noguchi S. “Health-related quality of life of patients with advanced
breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3,
randomized, controlled, BOLERO-2 trial.” Cancer. 2013 May 15;119(10):1908-15. doi:
10.1002/cncr.28010. PubMed PMID: 23504821.
12. Criscitiello C, Azim HA Jr, Agbor-tarh D, de Azambuja E, Piccart M, Baselga J, Eidtmann H, Di
Cosimo S, Bradbury I, Rubio IT. “Factors associated with surgical management following
neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the
NeoALTTO phase III trial.” Ann Oncol. 2013 Aug;24(8):1980-5. doi: 10.1093/annonc/mdt129.
PubMed PMID: 23567146.
13. Prat A, Baselga J. “Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal
therapy for the treatment of primary HER2-positive breast cancer: one more step toward
chemotherapy-free therapy.” J Clin Oncol. 2013 May 10;31(14):1703-6. doi:
10.1200/JCO.2012.48.4998. PubMed PMID: 23569319.
14. Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, Rodenas E, Hudis C, O'Shaughnessy
J, Baselga J. “A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients
with advanced or metastatic HER2-positive breast cancer.” Breast Cancer Res Treat. 2013
May;139(1):107-13. doi: 10.1007/s10549-013-2510-5. PubMed PMID: 23580070; PubMed Central
PMCID: PMC3646160. Study agent was not further developed
15. Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini
KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G,

 Piccart-Gebhart M. “Magnitude of trastuzumab benefit in patients with HER2-positive, invasive
lobular breast carcinoma: results from the HERA trial.” J Clin Oncol. 2013 Jun 1;31(16):1954-60.
doi: 10.1200/JCO.2012.46.2440. PubMed PMID: 23589556.
16. Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G,
Baselga J. “Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with
HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebocontrolled phase III study.” Oncologist. 2013;18(3):257-64. doi: 10.1634/theoncologist.2012-0448.
PubMed PMID: 23475636; PubMed Central PMCID: PMC3607520.
17. Goldhirsch A1, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C,
Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L,
Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I,
Leyland-Jones B, Baselga J. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast
cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21;382(9897):1021-8.
doi: 10.1016/S0140-6736(13)61094-6. Epub 2013 Jul 18.
18. Serra V, Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P,
Parra JL, Marlow S, Scaltriti M, Pérez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J.
“RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.” J Clin Invest. 2013
Jun;123(6):2551-63. doi: 10.1172/JCI66343. Erratum in: J Clin Invest. 2014 Mar 3;124(3):1418.
PubMed PMID: 23635776; PubMed Central PMCID: PMC3668839. BASIC SCIENCE.
19. André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H,
Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. “Targeting FGFR
with dovitinib (TKI258): preclinical and clinical data in breast cancer.” Clin Cancer Res. 2013 Jul
1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. PubMed PMID: 23658459.
20. Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo
A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A,
Groos J, Melezínková H, Awada A. “Randomized phase II study of the anti-epidermal growth factor
receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with
metastatic triple-negative breast cancer.” J Clin Oncol. 2013 Jul 10;31(20):2586-92. doi:
10.1200/JCO.2012.46.2408. PubMed PMID: 23733761. PMCID: PMC570519. Study was negative
and study agent was no further developed. N0 relationship with study agent or the field (old
study completed in 2002)
21. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M,
Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J,
Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. “Effect of visceral
metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast
cancer: subgroup analysis from the BOLERO-2 study.” Eur J Cancer. 2013 Aug;49(12):2621-32.
doi: 10.1016/j.ejca.2013.04.011. PubMed PMID: 23735704.
22. Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J,
Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A,
Rosen N, Engelman JA, Scaltriti M, Baselga J. “mTORC1 inhibition is required for sensitivity to
PI3K p110α inhibitors in PIK3CA-mutant breast cancer.” Sci Transl Med. 2013 Jul
31;5(196):196ra99. doi: 10.1126/scitranslmed.3005747. PubMed PMID: 23903756; PubMed Central
PMCID: PMC3935768.

 23. Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M,
Baselga J, Kufe D. “Targeting the MUC1-C oncoprotein downregulates HER2 activation and
abrogates trastuzumab resistance in breast cancer cells.” Oncogene. 2014 Jun 26;33(26):3422-31. doi:
10.1038/onc.2013.308. PubMed PMID: 23912457; PubMed Central PMCID: PMC3916940. BASIC
SCIENCE
24. Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L,
Grueso J, Hernández-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J.
“Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel
HER2V659E mutation.” Cancer Discov. 2013 Nov;3(11):1238-44. doi: 10.1158/2159-8290.CD-130132. PubMed PMID: 23950206.
25. Cortés J, Swain SM, Kudaba I, Hauschild M, Patel T, Grincuka E, Masuda N, McNally V, Ross G,
Brewster M, Marier JF, Trinh MM, Garg A, Nijem I, Visich J, Lum BL, Baselga J. “Absence of
pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.” Anticancer
Drugs. 2013 Nov;24(10):1084-92. doi: 10.1097/CAD.0000000000000016. PubMed PMID:
23969513.
26. Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras
MJ, Baselga J, Tabernero J. “Phase I pharmacokinetic and pharmacodynamic study of the first-inclass spliceosome inhibitor E7107 in patients with advanced solid tumors.” Clin Cancer Res. 2013
Nov 15;19(22):6296-304. doi: 10.1158/1078-0432.CCR-13-0485. PubMed PMID: 23983259. Study
agent was not further developed
27. Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart
M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J,
Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA 3rd. “Health-related
quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced
breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.” Curr Med
Res Opin. 2013 Nov;29(11):1463-73. doi: 10.1185/03007995.2013.836078. PubMed PMID:
23962028. Could not access the article
28. Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galván P,
Sapino A, Aglietta M, Baselga J, Scaltriti M. “Potential biomarkers of long-term benefit from singleagent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.” Mol Oncol. 2014
Feb;8(1):20-6. doi: 10.1016/j.molonc.2013.08.013. PubMed PMID: 24075779.
29. Azim HA Jr, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C,
Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, ToralPeña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M. “Circulating tumor cells and
response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO
phase III trial.” Breast. 2013 Dec;22(6):1060-5. doi: 10.1016/j.breast.2013.08.014. PubMed PMID:
24060577.
30. Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van
Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J,
Piccart M, Flamen P, Di Cosimo S. “18F-FDG PET/CT for early prediction of response to
neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results
from Neo-ALTTO.” J Nucl Med. 2013 Nov;54(11):1862-8. doi: 10.2967/jnumed.112.119271.
PubMed PMID: 24092940. Academic imaging study

 31. Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain
SM. “Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab,
trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled
phase III trial (CLEOPATRA).” Breast Cancer Res Treat. 2013 Nov;142(1):89-99. doi:
10.1007/s10549-013-2710-z. PubMed PMID: 24129974; PubMed Central PMCID: PMC3825296.
32. Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodríguez O, Guzman M, Sampath D, Nannini M,
Xiao Y, Wagle MC, Wu JQ, Wongchenko M, Hampton G, Ramakrishnan V, Lackner MR, Saura C,
Roda D, Cervantes A, Tabernero J, Patel P, Baselga J. “Evaluation and clinical analyses of
downstream targets of the Akt inhibitor GDC-0068.” Clin Cancer Res. 2013 Dec 15;19(24):6976-86.
doi: 10.1158/1078-0432.CCR-13-0978. PubMed PMID: 24141624.
33. Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN,
Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng
W, Cahana A, Taran T, Lebwohl D, Rugo HS. “Everolimus plus exemestane in postmenopausal
patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.” Adv Ther.
2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Erratum in: Adv Ther. 2014
Sep;31(9):1008-9. PubMed PMID: 24158787; PubMed Central PMCID: PMC3898123.
34. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD,
Nguyen LT, Xu Y, Egile C, Edelman G. “Phase I safety, pharmacokinetic, and pharmacodynamic
study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid
tumors.” Clin Cancer Res. 2014 Jan 1;20(1):233-45. doi: 10.1158/1078-0432.CCR-13-1777. Erratum
in: Clin Cancer Res. 2015 May 1;21(9):2192. PubMed PMID: 24166903. Study agent was not
further developed
35. Cortes, J., J. Baselga, Y. H. Im, S. A. Im, X. Pivot, G. Ross, E. Clark, A. Knott and S. M. Swain
(2013). "Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining
pertuzumab with trastuzumab and docetaxel in metastatic breast cancer." Ann Oncol 24(10): 26302635.
36. Vahdat LT, Vrdoljak E, Gómez H, Li RK, Bosserman L, Sparano JA, Baselga J, Mukhopadhyay P,
Valero V. “Efficacy and safety of ixabepilone plus capecitabine in elderly patients with
anthracycline- and taxane-pretreated metastatic breast cancer.” J Geriatr Oncol. 2013 Oct;4(4):34652. doi: 10.1016/j.jgo.2013.07.006. PubMed PMID: 24472478.
37. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C,
Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. “ESR1 ligandbinding domain mutations in hormone-resistant breast cancer.” Nat Genet. 2013. PMID: 24185512.
BASIC SCIENCE.
38. Pritchard KI, Burris HA, 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csoszi T,
Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez
Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. “Safety and Efficacy of
Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative,
Hormone Receptor-Positive Breast Cancer in BOLERO-2.” Clin Breast Cancer. 2013; 13(6):42132.e8. Epub 2013/11/26. PMID: 24267730.
39. Azim HA Jr, Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG Jr, Smith I,
Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart M,
de Azambuja E. “Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their

 association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.”
J
Clin Oncol. 2013 Dec 20;31(36):4504-11. doi: 10.1200/JCO.2013.50.9448. Erratum in: J Clin Oncol.
2014 Feb 1;32(4):365. PubMed PMID: 24248687.
40. Bardia A, Baselga J. “Neoadjuvant therapy as a platform for drug development and approval in
breast cancer.” Clin Cancer Res. 2013 Dec 1;19(23):6360-70. doi: 10.1158/1078-0432.CCR-13-0916.
Review. PubMed PMID: 24298066.
41. Baselga J, Manikhas A, Cortes J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D,
Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. “Phase III trial of
nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2positive metastatic breast cancer.” Ann Oncol. 2014. Epub 2014/01/10. PMID: 24401928. Drug not
approved. Negative study and study agent was never developed.
42. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gomez P, Semiglazov V,
Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez F, Gianni L, Baselga J.
“Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival
Outcomes in HER2-Positive Breast Cancer in the NOAH Study.” Clin Cancer Res. 2014; 20(2):51121. Epub 2014/01/21. PMID: 24443618.
43. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X,
De Stanchina E, Baselga J, Liu N, Chandarlapaty S, Rosen N. “Rapid induction of apoptosis by
PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.” Cancer Discov.
2014. Epub 2014/01/18. PMID: 24436048
44. Saura C, Bendell JC, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A,
Urruticoechea A, Beck JT, Ditomaso E, Sternberg DW, Massacesi C, Hirawat S, Dirix L, Baselga J.
“Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic
breast cancer that has progressed on trastuzumab-based therapy.” Clin Cancer Res. 2014. Epub
2014/01/29. PMID: 24470511.
45. Rodon J, Tawbi HA, Thomas AL, Stoller R, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam
D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC.
“A Phase 1, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Hedgehog
Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors.” Clin Cancer Res. 2014.
Epub 2014/02/14. PMID: 24523439.
46. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D,
Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou
C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S,
Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Jr., Pazdur R, Ditsch N,
Rastogi P, Eiermann W, von Minckwitz G. “Pathological complete response and long-term clinical
benefit in breast cancer: the CTNeoBC pooled analysis.” Lancet. 2014. Epub 2014/02/18. PMID:
24529560.
47. Papadopoulos K, Tabernero J, Markman B, Patnaik A, Tolcher A, Baselga J, Shi W, Egile C, RuizSoto R, Laird AD, Miles D, Lorusso PM. “Phase I safety, pharmacokinetic and pharmacodynamic
study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with
advanced solid tumors.” Clin Cancer Res. 2014. Epub 2014/03/04. PMID: 24583798. Negative
study agent. Agent was never developed

 48. Serra V, Eichhorn PJ, Garcia-Garcia C, Ibrahim YH, Prudkin L, Sanchez G, Rodriguez O, Anton P,
Parra JL, Marlow S, Scaltriti M, Perez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J.
“RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.” J Clin Invest. 2014;
124(3):1418. Epub 2014/03/05. PMID: 24590298; PMCID: PMCPmc3934174.BASIC SCIENCE.
No authors had disclosures
49. Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P,
Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P,
Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J,
Scaltriti M. “Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt
Pathway in Triple-Negative Breast Cancer.” Sci Signal. 2014; 7(318):ra29. Epub 2014/03/29. PMID:
24667376. PMCID: PMC4283215
50. Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth
M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy
M, Taran T, Burris HA, 3rd. “Incidence and time course of everolimus-related adverse events in
postmenopausal women with hormone receptor-positive advanced breast cancer: insights from
BOLERO-2.” Ann Oncol. 2014; 25(4):808-15. Epub 2014/03/13. PMID: 24615500; PMCID:
PMCPmc3969554.
51. Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M,
Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J. “A Pharmacodynamic/
Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver
Metastases.” Clin Cancer Res. 2014. Epub 2014/03/19. PMID: 24634378. Phase I clinical study,
study agent was not further developed
52. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F,
Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzu D,
Heinzmann D, Steinseifer J, Valagussa P, Baselga J. “Neoadjuvant and adjuvant trastuzumab in
patientswith HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised
controlled superiority trial with a parallel HER2-negative cohort.” Lancet Oncol. 2014. Epub
2014/03/25. PMID: 24657003.
53. Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, Cortes J. “Incidence of central nervous
system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab,
trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.” Ann Oncol.
2014. Epub 2014/04/02. PMID: 24685829.
54. Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP,
Baker NF, Galimi F, Beltran P, Baselga J. “Anticancer activity of the type I insulin-like growth
factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist,
conatumumab.” Target Oncol. 2014. Epub 2014/05/13. PMID: 24816908.
55. Balmana J, Tung NM, Isakoff SJ, Grana B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E,
Baselga J, Garber JE. “Phase I trial of olaparib in combination with cisplatin for the treatment of
patients with advanced breast, ovarian and other solid tumors.” Ann Oncol. 2014. Epub 2014/05/16.
PMID: 24827126.
56. Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P,
Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Tabernero J, Jimenez J,
Baselga J, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M. “Colon cancer-derived

 oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on
asymmetric dimerization and sensitive to cetuximab.” Mol Cancer. 2014; 13:141. Epub 2014/06/05.
PMID: 24894453; PMCID: PMCPmc4072491. BASIC SCIENCE.
57. Swain SM, Im YH, Im SA, Chan V, Miles D, Knott A, Clark E, Ross G, Baselga J. “Safety Profile
of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal
Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial
CLEOPATRA.” Oncologist. 2014; 19(7):693-701. Epub 2014/05/30. PMID: 24869931; PMCID:
PMCPmc4077449.
58. de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J,
Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B,
Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM. “Trastuzumab-Associated Cardiac Events at
8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01).” J Clin Oncol. 2014;
32(20):2159-65. Epub 2014/06/11. PMID: 24912899.
59. Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortes J, Parker JS, Perou CM, Baselga J.
“Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast
cancer.” J Natl Cancer Inst. 2014; 106(8). Epub 2014/08/21. PMID: 25139534. Biomarker Study.
60. De Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M,
Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Jr., Kim SB, Kuemmel
S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD,
Eidtmann H, Baselga J. “Lapatinib with trastuzumab for HER2-positive early breast cancer
(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their
association with pathological complete response.” Lancet Oncol. 2014; 15(10):1137-46. Epub
2014/08/19. PMID: 25130998.
61. Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P,
Saini KS, Sotiriou C, Campbell P, Dinh P, von Minckwitz G, Gelber RD, Dowsett M, Di Leo A,
Cameron D, Baselga J, Gnant M, Goldhirsch A, Norton L, Piccart M. “The AURORA initiative for
metastatic breast cancer.” Br J Cancer. 2014. Epub 2014/09/17. PMID: 25225904. CONCEPTUAL
paper.
62. Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo
HS, Deleu I, Burris HA, 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng
W, Taran T, Baselga J. “Everolimus plus exemestane for hormone-receptor-positive, human
epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from
BOLERO-2.” Ann Oncol. 2014. Epub 2014/09/19. PMID: 25231953.
63. Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M,
Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortes J, Baselga J, Perou CM, Prat A, Rubio IT,
Arribas J. “Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy.” J Natl
Cancer Inst. 2014; 106(11). Epub 2014/09/26. PMID: 25253614. BASIC SCIENCE
64. Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Cortes J, Kiger C, Germa C, Wang
K, Martin M, Baselga J, Kim SB. “Safety and efficacy of neratinib in combination with capecitabine
in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.” J Clin
Oncol. 2014; 32(32):3626-33. Epub 2014/10/08. PMID: 25287822.
65. DiCosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Brana I, Roda Perez D, Haines
BB, Zhang T, Winter C, Jha S, Xu Y, Frazier J, Klinghofer R, Leighton-Swayze A, Song Y,

 Ebbinghaus S, Baselga J. “Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R
monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.” Clin
Cancer Res. 2014. Epub 2014/10/17. PMID: 25320355. PMCID: PMC5705197. Preclinical and
Phase I study, Study agent was not further developed.
66. Hyman D, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT,
Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock
R, Erlander MG, Janku F, Abdel-Wahab O. “Prospective Blinded Study of BRAFV600E Mutation
Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders.” Cancer Discov. 2014.
Epub 2014/10/18. PMID: 25324352. Translational.
67. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM,
Flamand Y, Benes CH, Haber DA, Baselga J, Demetri GD. “Phase II study of olaparib in patients
with refractory Ewing sarcoma following failure of standard chemotherapy.” BMC Cancer. 2014;
14:813. Epub 2014/11/07. PMID: 25374341; PMCID: PMC4230717.
68. Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. “Biomarker Analyses in
CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth
Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer.” J Clin Oncol. 2014; 32(33):375361. Epub 2014/10/22. PMID: 25332247.
69. Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E,
Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desaiah D, Estrem ST, Paz-Ares L, Holdoff M,
Blakeley J, Lahn MM, Baselga J. “First-in-Human Dose Study of the Novel Transforming Growth
Factor-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer
and Glioma.” Clin Cancer Res. 2014. Epub 2014/11/27. PMID: 25424852. PMCID: PMC4337847.
Study agent was not further developed
70. Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J,
Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis CE, Eidtmann H,
Arribas J, Cortes J, De Azambuja E, Piccart M, Baselga J. “High HER2 expression correlates with
response to the combination of lapatinib and trastuzumab.” Clin Cancer Res. 2014. Epub 2014/12/04.
Pub 2/2015 PMID: 25467182.
71. Kovacs RJ, Maldonado G, Azaro A, Fernandez MS, Romero FL, Sepulveda-Sanchez JM, Corretti M,
Carducci M, Dolan M, Gueorguieva I, Cleverly AL, Pillay NS, Baselga J, Lahn MM. “Cardiac
Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a
First-in-Human Dose Study.” Cardiovasc Toxicol. 2014. Epub 2014/12/10. PubMed PMID:
25488804. PMCID: PMC4575352.
72. Rodon J, Carducci M, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E,
Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J,
Lahn MM, Baselga J. “Pharmacokinetic, pharmacodynamic and biomarker evaluation of
transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients
with advanced cancer.” Invest New Drugs. 2014. Epub 2014/12/23. PMID: 25529192. PMCID:
PMC4387272.
73. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M,
Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N.
“Feedback Suppression of PI3Kalpha Signaling in PTEN-Mutated Tumors Is Relieved by Selective

 Inhibition of PI3Kbeta.” Cancer Cell. 2014. Epub 2014/12/30. Pub 2014/12/24. PMID: 25544636.
PMCID: PMC4293347.
74. Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J,
Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton
L, Baselga J, Hudis C. “Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab
and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic
Breast Cancer.” J Clin Oncol. 2014. Epub 2014/12/31. PMID: 25547504. PMCID: PMC5747317.
75. Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C,
Fumagalli D, Jimenez J, Aura C, Prudkin L, Diaz-Delgado MC, de la Pena L, Loi S, Ellis C, Schultz
N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J. “PIK3CA Mutations Are
Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2Targeted Therapies in Breast Cancer.” J Clin Oncol. 2015. Epub 2015/01/07. PMID: 25559818.
PubMed Central PMCID: PMC5087318.
76. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A,
Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB,
Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J*,
Scaltriti M. “Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.” Nature.
2015 Feb 12;518(7538):240-4. doi: 10.1038/nature13948. Epub 2014 Nov 17. PubMed PMID:
25409150; PubMed Central PMCID: PMC4326538. *Corresponding author.
77. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM,
Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group..
“Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.” N Engl J Med.
2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. PubMed PMID: 25693012. PMCID:
PMC5584549.
78. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM,
Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry
WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM,
Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C,
Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S,
Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. “Genomic
Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic
Targets.” Cancer Discov. 2015 Nov;5(11):1164-77. doi: 10.1158/2159-8290.CD-15-0369. PubMed
PMID: 26410082; PubMed Central PMCID: PMC4916970. BASIC SCIENCE.
79. Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller
AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S,
Colinge J, Serra V, Nijman SM. “Targeting a cell state common to triple-negative breast cancers.”
Mol Syst Biol. 2015 Feb 19;11(1):789. doi: 10.15252/msb.20145664. PubMed PMID: 25699542;
PubMed Central PMCID: PMC4358660. BASIC SCIENCE.
80. Ugalde-Olano A, Egia A, Fernandez-Ruiz S, Loizaga-Iriarte A, Zuniga-Garcia P, Garcia S, Royo F,
Lacasa-Viscasillas I, Castro E, Cortazar AR, Zabala-Letona A, Martin-Martin N, ArruabarrenaAristorena A, Torrano-Moya V, Valcarcel-Jimenez L, Sanchez-Mosquera P, Caro-Maldonado A,
Gonzalez-Tampan J, Cachi-Fuentes G, Bilbao E, Montero R, Fernandez S, Arrieta E, Zorroza K,
Castillo-Martin M, Serra V, Salazar E, Macias-Camara N, Tabernero J, Baselga J, Cordon-Cardo C,

 Aransay AM, Villar AD, Iovanna JL, Falcon-Perez JM, Unda M, Bilbao R, Carracedo A.
“Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN.”
Mol Syst Biol.. 2015. Epub 2015/02/24. doi: 10.1016/j.ymeth.2015.02.005. PMID: 25697760. Epub
2015/02/19. doi: 10.1056/NEJMoa1413513. PubMed Central PMCID: PMC4503808. BASIC
SCIENCE.
81. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT,
Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J,
Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty
S*, Scaltriti M*, Baselga J*. “PI3K inhibition results in enhanced estrogen receptor function and
dependence in hormone receptor-positive breast cancer.” Sci Transl Med. 2015 Apr
15;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442. PubMed PMID: 25877889; PubMed Central
PMCID: PMC4433148. *Corresponding Authors.
82. Gil-Gil, M. J., M. Bellet, S. Morales, B. Ojeda, L. Manso, C. Mesia, E. Garcia-Martinez, N.
Martinez-Janez, M. Mele, A. Llombart, S. Pernas, P. Villagrasa, C. Blasco and J. Baselga (2015).
"Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary
chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the
phase II CAPRICE study." Breast Cancer Res Treat 151(3): 597-606. Academic study
83. O, Landry HM, Fuller JE, Santini JT Jr, Baselga J, Tepper RI, Cima MJ, Langer R. “An implantable
microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.” Sci Transl Med.
2015 Apr 22;7(284):284ra57. doi: 10.1126/scitranslmed.3010564. PubMed PMID: 25904741;
PubMed Central PMCID: PMC4825177. BASIC SCIENCE
84. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse
N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó
C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M*, Baselga J*. “AXL mediates
resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and
esophageal squamous cell carcinomas.” Cancer Cell. 2015 Apr 13;27(4):533-46. doi:
10.1016/j.ccell.2015.03.010. PubMed PMID: 25873175; PubMed Central PMCID: PMC4398915.
*Corresponding Authors.
85. Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Pena L, Ellis C,
Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J. “Benefit to neoadjuvant anti-Human
Epidermal Growth Factor Receptor 2 (HER2)-targeted therapies in HER2-positive primary breast
cancer is independent of Phosphatase and tensin homolog deleted from chromosome 10 (PTEN)
status.” Ann Oncol.2015. Epub 2015/04/09. PMID: 25851628. PubMed Central PMCID:
PMC5006510.
86. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J,
Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS,
Penuel E, Amler LC, Pirzkall A, Baselga J. “Safety and Pharmacokinetics/Pharmacodynamics of the
First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic
Epithelial Tumors.” Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-142412. PubMed PMID: 26034219. PMCID: PMC5705193. Inconsistent. Study agent was not
developed further.
87. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis
CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. “Tumor-Infiltrating

 Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in
HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary
Analysis of the NeoALTTO Trial.” JAMA Oncol. 2015 Jul;1(4):448-54. doi:
10.1001/jamaoncol.2015.0830. Erratum in: JAMA Oncol. 2015 Jul;1(4):544. JAMA Oncol. 2015
Nov;1(8):1172. Nucifero, Paolo [corrected to Nuciforo, Paolo]. PubMed PMID: 26181252; PubMed
Central PMCID: PMC5551492.
88. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL,
Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E,
Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J.
“Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.” N Engl J Med. 2015
Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. PubMed PMID: 26287849; PubMed Central
PMCID: PMC4971773.
89. Baselga J, Bhardwaj N, Cantley LC, DeMatteo R, DuBois RN, Foti M, Gapstur SM, Hahn WC,
Helman LJ, Jensen RA, Paskett ED, Lawrence TS, Lutzker SG, Szabo E. “AACR Cancer Progress
Report 2015.” Clin Cancer Res. 2015 Oct 1;21(19 Suppl):S1-128. doi: 10.1158/1078-0432.CCR-151846. PubMed PMID: 26429991; PubMed Central PMCID: PMC5001568. Opinion piece, no
disclosures by any author
90. Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, 3rd, Pritchard KI, Campone M, Noguchi
S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg
A, McDonald ER, 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J.
“Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive,
Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From
BOLERO-2.” J Clin Oncol. 2015. Epub 2015/10/28. doi: 10.1200/jco.2014.60.1971. PMID:
26503204. PubMed Central PMCID: PMC5070556.
91. Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K,
Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di
Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J.
“SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus
paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.” Breast Cancer
Res Treat. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. PubMed PMID: 26536871;
PubMed Central PMCID: PMC4971774. Study agent was not developed further.
92. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA,
Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP,
Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Dieras
V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter
T, Gelber RD, Perez EA. “Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth
Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant
Lapatinib and/or Trastuzumab Treatment Optimization Trial.” J Clin Oncol. 2015. Epub 2015/11/26.
doi: 10.1200/jco.2015.62.1797. PMID: 26598744. PMCID: PMC4872016.
93. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, Berger MF, Ladanyi M.
“Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing
enabling next-generation targeted therapy trials.” Drug Discov Today. 2015 Dec;20(12):1422-8. doi:
10.1016/j.drudis.2015.08.005. PubMed PMID: 26320725; PubMed Central PMCID: PMC4940024.
Conceptual.

 94. García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón
P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L,
Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. “MEK
plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of
Colorectal Cancer.” Clin Cancer Res. 2015 Dec 15;21(24):5499-510. doi: 10.1158/1078-0432.CCR14-3091. PubMed PMID: 26272063; PubMed Central PMCID: PMC5087596. BASIC SCIENCE
95. Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M,
Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD; HERA Study Team..
“Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free
interval: the HERA trial experience.” Breast Cancer Res Treat. 2016 Jan;155(1):127-32. doi:
10.1007/s10549-015-3656-0. PubMed PMID: 26708471; PubMed Central PMCID: PMC4947530.
Conceptual
96. Grego-Bessa J, Bloomekatz J, Castel P, Omelchenko T, Baselga J, Anderson KV. “The tumor
suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium.” Elife.
2016 Jan 26;5:e12034. doi: 10.7554/eLife.12034. PubMed PMID: 26809587; PubMed Central
PMCID: PMC4739759. BASIC SCIENCE
97. Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, CohenAubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O,
Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M,
Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Héritier S,
Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A,
Emile JF, Rosen N, Gruber TA, Abdel-Wahab O. “Diverse and Targetable Kinase Alterations Drive
Histiocytic Neoplasms.” Cancer Discov. 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-150913. PubMed PMID: 26566875; PubMed Central PMCID: PMC4744547. Translational work.
98. Scaltriti M, Elkabets M, Baselga J. “Molecular Pathways: AXL, a Membrane Receptor Mediator of
Resistance to Therapy.” Clin Cancer Res. 2016 Mar 15;22(6):1313-7. doi: 10.1158/1078-0432.CCR15-1458. Epub 2016 Jan 13. Review. PubMed PMID: 26763248; PubMed Central PMCID:
PMC4957976. BASIC SCIENCE review
99. Iyengar NM, Fornier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM,
Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME,
Chen MF, Patil S, Baselga J, Norton L, Hudis CA, Dang CT. “A Pilot Study of Dose-Dense
Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.”
Clinical breast cancer. 2016 Apr;16(2):87-94. Epub 2015/10/12. doi: 10.1016/j.clbc.2015.09.009.
PubMed PMID: 26454612; PubMed Central PMCID: PMCPmc4968930. Report from an old study
conducted in 2013
100.
Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino E, Samant M, Olsen S, de
Haas S, Pegram MD. “Relationship Between Tumor Biomarkers and Efficacy in EMILIA, a Phase III
Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.” Clin Cancer Res.
2016 Aug. Epub 2016/02/28. doi: 10.1158/1078-0432.ccr-15-2499. PMID: 26920887. PMCID:
PMC5485412.
101.
Piscuoglio S, Ng CK, Murray M, Burke KA, Edelweiss M, Geyer FC, Macedo GS, Inagaki A,
Papanastasiou AD, Martelotto LG, Marchio C, Lim RS, Ioris RA, Nahar PK, Bruijn ID, Smyth L,
Akram M, Ross D, Petrini JH, Norton L, Solit DB, Baselga J, Brogi E, Ladanyi M, Weigelt B, Reis-

 Filho JS. “Massively parallel sequencing of phyllodes tumours of the breast reveals actionable
mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of
progression.” J Pathol. 2016 Mar;238(4):508-18. doi: 10.1002/path.4672. PubMed PMID: 26832993;
PubMed Central PMCID: PMC4962788. BASIC SCIENCE
102.
Carmona FJ, Montemurro F, Kannan S, Rossi V, Verma C, Baselga J, Scaltriti M. “AKT
signaling in ERBB2-amplified breast cancer.” Pharmacol Ther. 2016 Feb;158:63-70. doi:
10.1016/j.pharmthera.2015.11.013. Review. PubMed PMID: 26645663; PubMed Central PMCID:
PMC4747800. BASIC SCIENCE
103.
Ebbesen SH, Scaltriti M, Bialucha CU, Morse N, Kastenhuber ER, Wen HY, Dow LE,
Baselga J, Lowe SW. “Pten loss promotes MAPK pathway dependency in HER2/neu breast
carcinomas.” Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3030-5. doi:
10.1073/pnas.1523693113. Epub 2016 Feb 29. PubMed PMID: 26929372; PubMed Central PMCID:
PMC4801318.
104.
Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, Bague S, Scaltriti
M, Antonescu CR, Baselga E, Baselga J. “Somatic PIK3CA mutations as a driver of sporadic venous
malformations.” Sci Transl Med. 2016 Mar 30;8(332):332ra42. doi: 10.1126/scitranslmed.aaf1164.
PubMed PMID: 27030594; PubMed Central PMCID: PMC4962922.
105.
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A,
Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M,
Martin LA, Turner NC, Serra V. “Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in
Estrogen Receptor-Positive Breast Cancer.” Cancer Res. 2016 Apr 15;76(8):2301-13. doi:
10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28. Erratum in: Cancer Res. 2016 Oct
1;76(19):5907. PubMed PMID: 27020857; PubMed Central PMCID: PMC5426059. BASIC
SCIENCE
106.
Toska E, Baselga J. “Pharmacology in the Era of Targeted Therapies: The Case of PI3K
Inhibitors.” Clin Cancer Res. 2016 May 1;22(9):2099-101. doi: 10.1158/1078-0432.CCR-16-0038.
PubMed PMID: 26957555; PubMed Central PMCID: PMC4946572. Review refering to ongoing
clinical trials with PI3K inhibitors
107.
Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, Morris L, Ganly I,
Shiao SL, Powell SN, Chung CH, Scaltriti M, Baselga J. “Taselisib (GDC-0032), a Potent β-Sparing
Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas
Containing Activating PIK3CA Alterations.” Clin Cancer Res. 2016 Apr 15;22(8):2009-19. doi:
10.1158/1078-0432.CCR-15-2245. PubMed PMID: 26589432; PubMed Central PMCID:
PMC4870591. BASIC SCIENCE
108.
Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury
I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E,
de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C. “RNA
Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the
NeoALTTO Randomized Clinical Trial.” JAMA Oncol. 2016 Sep 29. doi:
10.1001/jamaoncol.2016.3824. [Epub ahead of print] PubMed PMID: 27684533; PubMed Central
PMCID: PMC5374044.
109.
Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant
M, Hortobagyi G, Baselga J, Moynahan ME. “Prevalence of ESR1 Mutations in Cell-Free DNA and

 Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.”
JAMA Oncol. 2016 Oct 1;2(10):1310-1315. doi: 10.1001/jamaoncol.2016.1279. PubMed PMID:
27532364; PubMed Central PMCID: PMC5063698. Translational endpoint. Senior authors had
no disclosures ( Michael Gnant, MD; Gabriel Hortobagyi, MD; Jose Baselga, MD, PhD; Mary
Ellen Moynahan, MD)
110.
Wehrenberg-Klee E, Turker NS, Heidari P, Larimer B, Juric D, Baselga J, Scaltriti M,
Mahmood U. “Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.” J
Nucl Med. 2016 Sep;57(9):1413-9. doi: 10.2967/jnumed.115.169417. Epub 2016 Apr 14. PubMed
PMID: 27081168; PubMed Central PMCID: PMC5093919.
111.
Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena
PV, Gardner EE, Poirier JT, Rudin CM, Baselga J, Haimovitz-Friedman A, Heller DA. “P-selectin is
a nanotherapeutic delivery target in the tumor microenvironment.” Sci Transl Med. 2016 Jun
29;8(345):345ra87. doi: 10.1126/scitranslmed.aaf7374. PubMed PMID: 27358497; PubMed Central
PMCID: PMC5064151.
112.
Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF,
Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval
T, Baselga J, Norton L, Hudis CA, Dang CT. “Weekly paclitaxel with trastuzumab and pertuzumab
in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated
progression-free survival results from a phase II study.” Breast Cancer Res Treat. 2016
Jul;158(1):91-7. doi: 10.1007/s10549-016-3851-7. Epub 2016 Jun 15. PubMed PMID: 27306421;
PubMed Central PMCID: PMC5017157.
113.
Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M,
Chandarlapaty S, Brogi E, Alessi DR, Baselga J*, Scaltriti M.* “PDK1-SGK1 Signaling Sustains
AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.” Cancer Cell.
2016 Aug 8;30(2):229-42. doi: 10.1016/j.ccell.2016.06.004. Epub 2016 Jul 21. PubMed PMID:
27451907; PubMed Central PMCID: PMC4982440. *Corresponding authors. BASIC SCIENCE
114.
Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, Baselga J, Cross D, Eyers PA,
Alessi DR. “The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating
mTORC1 and tumour growth.” EMBO J. 2016 Sep 1;35(17):1902-22. doi:
10.15252/embj.201693929. Epub 2016 Aug 1. PubMed PMID: 27481935; PubMed Central PMCID:
PMC5007552.BASIC SCIENCE
115.
Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J,
Ang KK, Rosenthal DI. “Association of human papillomavirus and p16 status with mucositis and
dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab:
Assessment from a phase 3 registration trial.” Eur J Cancer. 2016 Sep;64:1-11. doi:
10.1016/j.ejca.2016.05.008. Epub 2016 Jun 17. PubMed PMID: 27323346; PubMed Central PMCID:
PMC5027878. Explorative endpoint in phase III study completed 2002
116.
Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C,
Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J. “PIK3CA
mutations are associated with reduced pathological complete response rates in primary HER2positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating
lapatinib and trastuzumab.” Ann Oncol. 2016 Aug;27(8):1519-25. doi: 10.1093/annonc/mdw197.
PubMed PMID: 27177864. NIHMS 881148 Translational endpoints, no clinical applications.

 117.
Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L,
Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, Garcia S, Macías I, Salvador F,
Domenici G, Rueda OM, Zabala-Letona A, Arruabarrena-Aristorena A, Zúñiga-García P, CaroMaldonado A, Valcárcel-Jiménez L, Sánchez-Mosquera P, Varela-Rey M, Martínez-Chantar ML,
Anguita J, Ibrahim YH, Scaltriti M, Lawrie CH, Aransay AM, Iovanna JL, Baselga J, Caldas C,
Barrio R, Serra V, Vivanco Md, Matheu A, Gomis RR, Carracedo A. “Stratification and therapeutic
potential of PML in metastatic breast cancer.” Nat Commun. 2016 Aug 24;7:12595. doi:
10.1038/ncomms12595. PubMed PMID: 27553708; PubMed Central PMCID: PMC4999521.
BASIC SCIENCE.
118.
Bonner J, Giralt J, Harari P, Spencer S, Schulten J, Hossain A, Chang SC, Chin S, Baselga J.
“Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and
Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.” JAMA Otolaryngol Head
Neck Surg. 2016 Sep 1;142(9):842-9. doi: 10.1001/jamaoto.2016.1228. PubMed PMID: 27389475;
PubMed Central PMCID: PMC5025385.
119.
Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval
J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P,
Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J,
Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C. “A
Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer
Compounds.” Cell. 2016 Sep 22;167(1):260-274.e22. doi: 10.1016/j.cell.2016.08.041. PubMed
PMID: 27641504; PubMed Central PMCID: PMC5037319. BASIC SCIENCE.
120.
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa
DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL,
Baselga J, Pusztai L. “Pathway level alterations rather than mutations in single genes predict
response to HER2-targeted therapies in the neo-ALTTO trial.” Ann Oncol. 2016 Sep 29. pii:
mdw434. PubMed PMID: 28177460. PMCID: PMC5834036. BASIC SCIENCE.
121.
Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, Baselga J,
Garraway LA. “Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast
Cancer.” Cancer Discov. 2016 Oct;6(10):1134-1147. PubMed PMID: 27604488; PubMed Central
PMCID: PMC5050154. BASIC SCIENCE
122.
Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, Baselga J, Rosen N, Chandarlapaty S.
“Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of
ER signaling and dependence.” Oncogene. 2017 Apr 20;36(16):2255-2264. doi:
10.1038/onc.2016.379. Epub 2016 Oct 17. PubMed PMID: 27748766; PubMed Central PMCID:
PMC5393973.BASIC SCIENCE
123.
Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S,
Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA,
Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N,
Geyer M, Serra V, Lim E, Shapiro GI. “CDK12 Inhibition Reverses De Novo and Acquired PARP
Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.”
Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077. PubMed PMID:
27880910; PubMed Central PMCID: PMC5176643.BASIC SCIENCE

 124.
Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R,
Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM,
Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A. “A First-in-Human Phase I
Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of
AKT in Patients with Solid Tumors.” Cancer Discov. 2017 Jan;7(1):102-113. doi: 10.1158/21598290.CD-16-0512. Epub 2016 Nov 21. PubMed PMID: 27872130; PubMed Central PMCID:
PMC5463454.
125.
Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M,
Viñals F, Baselga J, Casanovas O, Graupera M. “Therapeutic Benefit of Selective Inhibition of
p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.” Clin Cancer Res. 2016 Dec
1;22(23):5805-5817. Epub 2016 May 25. PubMed PMID: 27225693; PubMed Central PMCID:
PMC5338478. BASIC SCIENCE.
126.
Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga
J, Michiels S, Loi S. “:Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer
treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis
of the CLEOPATRA study.” Lancet Oncol. 2017 Jan;18(1):52-62. doi: 10.1016/S14702045(16)30631-3. Epub 2016 Dec 7. PubMed PMID: 27964843; PubMed Central PMCID:
PMC5477653. No clinical implications.
127.
Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J,
Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S,
Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S. “Activating ESR1 Mutations
Differentially Affect the Efficacy of ER Antagonists.” Cancer Discov. 2017 Mar;7(3):277-287. doi:
10.1158/2159-8290.CD-15-1523. PubMed PMID: 27986707; PubMed Central PMCID:
PMC5340622. BASIC SCIENCE
128.
Wang Y, Ayres K, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer EP, Fredrickson J,
Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. “18F-fluoroestradiol PET/CT
Measurement of Estrogen Receptor Suppression During a Phase I Trial of the Novel Estrogen
Receptor-targeted Therapeutic GDC-0810.” Clin Cancer Res. 2016 Dec 23. pii:
clincanres.2197.2016. doi: 10.1158/1078-0432.CCR-16-2197. [Epub ahead of print] PubMed PMID:
28011460. PMCID: PMC5474190. Imaging Study
129.
Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B,
Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. “Next-Generation Assessment
of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation
in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.” J
Mol Diagn. 2017 Mar;19(2):244-254. doi: 10.1016/j.jmoldx.2016.09.010. Epub 2016 Dec 25.
PubMed PMID: 28027945; PubMed Central PMCID: PMC5397722. MSKCC internal technology
paper
130.
Osmanbeyoglu HU, Toska E, Chan C, Baselga J, Leslie CS. “Pancancer modelling predicts
the context-specific impact of somatic mutations on transcriptional programs.” Nat Commun. 2017
Jan 31;8:14249. doi: 10.1038/ncomms14249. PubMed PMID: 28139702; PubMed Central PMCID:
PMC5290314.BASIC SCIENCE

 131.
Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie
MS, Yoo B, Cortes J, Baselga J. “Incidence and management of diarrhea in patients with HER2positive breast cancer treated with pertuzumab.” Ann Oncol. 2017 Jan 5. pii: mdw695. doi:
10.1093/annonc/mdw695. [Epub ahead of print] PubMed PMID: 28057664. PMCID: PMC5834072.
132.
Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, Yu AF, Argolo D,
Smyth LM, Modi S, Schweber S, Boafo C, Patil S, Norton L, Baselga J, Hudis CA, Dang C.
“Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by
Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast
Cancer: A Single Center Experience.” Oncologist. 2017 Feb;22(2):139-143. doi:
10.1634/theoncologist.2016-0268. Epub 2017 Feb 6. PubMed PMID: 28167568; PubMed Central
PMCID: PMC5330708. Inconsistent, middle author
133.
Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F,
Hortobagyi GN, Baselga J, Chandarlapaty S. "Correlation between PIK3CA mutations in cell-free
DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.” Br
J Cancer. 2017 Mar 14;116(6):726-730. doi: 10.1038/bjc.2017.25. Epub 2017 Feb 9. PubMed PMID:
28183140; PubMed Central PMCID: PMC5355930.Translational. Does not imply any change in
clinical management or study agent use. I had reported disclosures in the original publication
134.
Hyman DM, Taylor BS, Baselga J. “Implementing Genome-Driven Oncology.” Cell. 2017
Feb 9;168(4):584-599. doi: 10.1016/j.cell.2016.12.015. Review. PubMed PMID: 28187282; PubMed
Central PMCID: PMC5463457. Conceptual paper.
135.
Mizrachi A, Shamay Y, Shah J, Brook S, Soong J, Rajasekhar VK, Humm JL, Healey JH,
Powell SN, Baselga J, Heller DA, Haimovitz-Friedman A, Scaltriti M. “Tumour-specific PI3K
inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.” Nat
Commun. 2017 Feb 13;8:14292. doi: 10.1038/ncomms14292. PubMed PMID: 28194032; PubMed
Central PMCID: PMC5316830. BASIC SCIENCE
136.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E,
Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, LeylandJones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team.. “11 years'
follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final
analysis of the HERceptin Adjuvant (HERA) trial.” Lancet. 2017 Mar 25;389(10075):1195-1205.
doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. PubMed PMID: 28215665; PubMed
Central PMCID: PMC5465633.
137.
Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez S, Savage H,
Sampath D, Salphati L, Lin R, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J. “Phase I Dose
Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid
Tumors.” Cancer Discoverv. 2017 Mar 22. pii: CD-16-1080. doi: 10.1158/2159-8290.CD-16-1080.
[Epub ahead of print] PubMed PMID: 28331003. PMCID: PMC5501742.
138.
Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN,
Scaltriti M, Leslie CS, Armstrong SA*, Baselga J*. “PI3K pathway regulates ER-dependent
transcription in breast cancer through the epigenetic regulator KMT2D.” Science. 2017 Mar
24;355(6331):1324-1330. doi: 10.1126/science.aah6893. PubMed PMID: 28336670. PMCID:
PMC5485411. PMCID: PMC5485411. *Corresponding authors. BASIC SCIENCE

 139.
Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra
R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg
MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris
MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB,
Ladanyi M, Riely GJ. “Prospective Comprehensive Molecular Characterization of Lung
Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.” Cancer
Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23. PubMed
PMID: 28336552. PubMed Central PMCID: PMC5482929. BASIC SCIENICE, conceptual.
140.
Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R,
Scheinberg DA, Baselga J, Wendel HG, Younes A. “Panobinostat acts synergistically with ibrutinib
in diffuse large B cell lymphoma cells with MyD88 L265 mutations.” JCI Insight. 2017 Mar
23;2(6):e90196. doi: 10.1172/jci.insight.90196. PubMed PMID: 28352655; PubMed Central PMCID:
PMC5358483. BASIC SCIENCE.
141.
Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S,
Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H,
Huober J, Brase JC, Samira M, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C,
Arteaga CL. “HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of
resistance to dual therapeutic blockade of HER2.” Clin Cancer Res. 2017 Apr 5. pii:
clincanres.2287.2016. doi: 10.1158/1078-0432.CCR-16-2287. [Epub ahead of print] PubMed PMID:
28381415. PMCID: PMC5540793. BASIC SCIENCE.
142.
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty
D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman
JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN,
Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J,
Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H,
Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE,
Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas
SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR,
Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA,
Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM,
Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra
DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.
“Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000
patients.” Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. PubMed
PMID: 28481359; PubMed Central PMCID: PMC5461196. BASIC SCIENCE.
143.
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, ElKhoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N,
Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A,
Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji
U, Baselga J, Taylor BS. “AKT Inhibition in Solid Tumors With AKT1 Mutations.” J Clin Oncol.
2017 May 10:JCO2017730143. doi: 10.1200/JCO.2017.73.0143. [Epub ahead of print] PubMed
PMID: 28489509. PMCID:PMC5501365
144.
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K,
Hoersch S, Xu J, Green M, Gianni L. “Trastuzumab emtansine versus capecitabine plus lapatinib in

 patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive
analysis of final overall survival results from a randomised, open-label, phase 3 trial.” Lancet Oncol.
2017 May 16. pii: S1470-2045(17)30312-1. doi: 10.1016/S1470-2045(17)30312-1. [Epub ahead of
print] PubMed PMID: 28526536. PMCID: PMC5531181.
145.
Dickler MN, Tolaney S, Rugo HS, Cortés J, Dieras V, Patt DA, Wildiers H, Hudis CA,
O'Shaughnessy JA, Zamora E, Yardley D, Frenzel M, Koustenis AG, Baselga J. “MONARCH 1, a
phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with
refractory HR+/HER2- metastatic breast cancer.” Clin Cancer Res. 2017 May 22. pii:
clincanres.0754.2017. doi: 10.1158/1078-0432.CCR-17-0754. [Epub ahead of print] PubMed PMID:
28533223. PMCID: PMC5581697.
146.
Baselga J*, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W,
Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda
N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone
M. “Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptorpositive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebocontrolled, phase 3 trial.” Lancet Oncol. 2017 May 30. pii: S1470-2045(17)30376-5. doi:
10.1016/S1470-2045(17)30376-5. [Epub ahead of print] PubMed PMID: 28576675. *Corresponding
Author. PMCID: PMC5549667.
147.
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ,
Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D,
Jones MB, Rugo HS. “A phase II study of combined ridaforolimus and dalotuzumab compared with
exemestane in patients with estrogen receptor-positive breast cancer.” Breast Cancer Res Treat. 2017
Jun;163(3):535-544. doi: 10.1007/s10549-017-4199-3. Epub 2017 Mar 21. PubMed PMID:
28324268; PubMed Central PMCID: PMC5448790. Results were negative since the combination
was found not to be more effective. Study agents were never developed
148.
Baselga J*, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L,
Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Patricia M, Huang
L, Meinhardt G, Zhang J, Schwartzberg LS. “RESILIENCE: Phase III Randomized, Double-Blind
Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally
Advanced or Metastatic HER2-Negative Breast Cancer.” Clin Breast Cancer. 2017 May 22. pii:
S1526-8209(17)30005-8. doi: 10.1016/j.clbc.2017.05.006. [Epub ahead of print] PubMed PMID:
28830796. PubMed Central PMCID: PMC5699974. *Corresponding author. Results were negative
since the combination was found not to be more effective. Study agent was never developed.
149.
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R,
Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM,
Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann
MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D,
Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ,
Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. “OncoKB: A Precision
Oncology Knowledge Base.” JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub
2017 May 16. PubMed PMID: 28890946; PMCID: PMC5586540. Conceptual paper.

 150.
von Minckwitz G*, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T,
Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart
M, Baselga J*; APHINITY Steering Committee and Investigators.. “Adjuvant Pertuzumab and
Trastuzumab in Early HER2-Positive Breast Cancer.” N Engl J Med. 2017 Jun 5. doi:
10.1056/NEJMoa1703643. [Epub ahead of print] PubMed PMID: 28581356. *Co-corresponding
authors. PMCID:PMC5538020.
151.
AACR Project GENIE Consortium.. “AACR Project GENIE: Powering Precision Medicine
through an International Consortium.” Cancer Discov. 2017 Aug;7(8):818-831. doi: 10.1158/21598290.CD-17-0151. Epub 2017 Jun 1. PubMed PMID: 28572459. PMCID: PMC5611790. BASIC
SCIENCE
152.
Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, TaylorWeiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes
ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS,
Gabriel SB, Meyerson M, Golub TR, Baselga J, Hidalgo-Miranda A, Shioda T, Bernards A, Lander
ES, Getz G. “Recurrent and functional regulatory mutations in breast cancer.” Nature. 2017 Jun 28.
doi: 10.1038/nature22992. [Epub ahead of print] PubMed PMID: 28658208. PMCID: PMC5563978.
BASIC SCIENCE
153.
Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S,
Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P,
Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D,
van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A,
Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, ZuñigaGarcía P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, CastilloMartín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D,
Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar
ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD,
Marjon K, Carracedo A. “mTORC1-dependent AMD1 regulation sustains polyamine metabolism in
prostate cancer.” Nature. 2017 Jun 28. doi: 10.1038/nature22964. [Epub ahead of print] PubMed
PMID: 28658205. PMCID: PMC5505479. BASIC SCIENCE
154.
Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M,
Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB,
Denker A, Baselga J. “A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane
compared with ridaforolimus and exemestane in patients with advanced breast cancer.” Breast
Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4375-5. [Epub ahead of print] PubMed
PMID: 28681171. PMCID: PMC5709225. Study agents were never developed.
155.
Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM,
Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker
S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti
V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K,
Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH,
Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale
G, Watanabe T, Whelan TJ, Xu B. “De-escalating and escalating treatments for early-stage breast
cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early

 Breast Cancer 2017.” Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.
PubMed PMID: 28838210. Since publication, I have stepped down from the consensus panel as a
result of me joining the BMS board.
156.
Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C,
Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators..
“Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triplenegative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase
2 trial.” Lancet Oncol. 2017 Aug 8. pii: S1470-2045(17)30450-3. doi: 10.1016/S14702045(17)30450-3. [Epub ahead of print] PubMed PMID: 28800861. PMCID: PMC5626630.
157.
Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, Hyman DM, Solit DB,
Robson ME, Baselga J, Arcila ME, Ladanyi M, Tallman MS, Levine RL, Berger MF. “TherapyRelated Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated
with Adverse Clinical Outcomes.” Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4. doi:
10.1016/j.stem.2017.07.010. Epub 2017 Aug 10. PubMed PMID: 28803919; PubMed Central
PMCID: PMC5591073. BASIC SCIENCE
158.
Schram AM, Reales D, Galle J, Cambria R, Durany R, Feldman D, Sherman E, Rosenberg J,
D'Andrea G, Baxi S, Janjigian Y, Tap W, Dickler M, Baselga J, Taylor BS, Chakravarty D, Gao J,
Schultz N, Solit DB, Berger MF, Hyman DM. “Oncologist use and perception of large panel nextgeneration tumor sequencing.” Ann Oncol. 2017 Sep 1;28(9):2298-2304. doi:
10.1093/annonc/mdx294. PubMed PMID: 28911072. PMCID PMC5834089. Conceptual
159.
Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A,
Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M,
Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V,
Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA,
Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer
RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M,
Robson ME, Offit K. “Mutation Detection in Patients With Advanced Cancer by Universal
Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline
Testing.” JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. PubMed PMID:
28873162. PMCID: PMC5611881. Conceptual
160.
Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J,
Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian
X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. “A phase I open-label doseescalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous
cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric
cancer.” BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6. PubMed PMID:
28899363; PubMed Central PMCID: PMC5596462. At the time of publication the drug was no
further being developed.
161.
Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo
B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart MJ, Von
Minckwitz G, Baselga J, Loi S. “Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women
with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial
(NeoPHOEBE).” Eur J Cancer. 2017 Sep 15;85:133-145. doi: 10.1016/j.ejca.2017.08.020. [Epub
ahead of print] PubMed PMID: 28923573. PMCID: PMC5640494.

 162.
Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, Su W, Wang L, Joelson A,
Cercek A, Baselga J, de Stanchina E, Saltz L, Berger MF, Solit DB, Rosen N. “Mechanisms of
acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and
are sensitive to its inhibition.” Cancer Res. 2017 Sep 26. pii: canres.0768.2017. doi: 10.1158/00085472.CAN-17-0768. [Epub ahead of print] PubMed PMID: 28951457. PMCID: PMC5712250.
BASIC SCIENCE
163.
Baselga J, Coleman RE, Cortés J, Janni W. “Advances in the management of HER2-positive
early breast cancer.” Crit Rev Oncol Hematol. 2017 Nov;119:113-122. doi:
10.1016/j.critrevonc.2017.10.001. Epub 2017 Oct 4. Review. PubMed PMID: 29042085; PubMed
Central PMCID: PMC5662944.
164.
Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri
JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab
O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM. “Vemurafenib for BRAF V600-Mutant
Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the HistologyIndependent, Phase 2, Open-label VE-BASKET Study.” JAMA Oncol. 2017 Nov 29. doi:
10.1001/jamaoncol.2017.5029. [Epub ahead of print] PubMed PMID: 29188284. PMCID:
PMC5844839.
165.
Chang MT, Shrestha Bhattarai T, Schram AM, Bielski CM, Donoghue MTA, Jonsson P,
Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J,
Sumer SO, Kundra R, Razavi P, Li BT, Reales DN, Socci ND, Jayakumaran G, Zehir A, Benayed R,
Arcila ME, Chandarlapaty S, Ladanyi M, Schultz N, Baselga J, Berger MF, Rosen N, Solit DB,
Hyman DM, Taylor BS. “Accelerating discovery of functional mutant alleles in cancer.” Cancer
Discov. 2017 Dec 15. pii: CD-17-0321. doi: 10.1158/2159-8290.CD-17-0321. [Epub ahead of print]
PubMed PMID: 29247016. PMCID: PMC5809279. BASIC SCIENCE
166.
Shukla, N., S. S. Roberts, M. O. Baki, Q. Mushtaq, P. E. Goss, B. H. Park, G. Gundem, K.
Tian, H. Geiger, K. Redfield, G. Behr, R. Benayed, A. Zehir, J. F. Hechtman, R. B. Darnell, E.
Papaemmanuil, M. Ladanyi, N. Ku, A. L. Kung, J. Baselga, A. Drilon and D. M. Hyman (2017).
"Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory
Breast Carcinoma." JCO Precis Oncol 2017. Case report, no relationship with company.
167.
Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di
Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M,
Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart M, Suter
T, de Azambuja E. “Cardiac biomarkers for early detection and prediction of trastuzumab and/or
lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a
NeoALTTO sub-study (BIG 1-06)”. Breast Cancer Res Treat. 2017 Dec 27. doi: 10.1007/s10549017-4628-3. [Epub ahead of print] PubMed PMID: 29280043. PMCID: PMC5843537. No further
development for early breast cancer; findings not applicable to clinical practice.
168.
Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C,
Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume
BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja E. “The use of breast imaging
for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2positive breast cancer: Results from Neo-ALTTO.” Eur J Cancer. 2018 Jan;89:42-48. doi:

 10.1016/j.ejca.2017.10.036. Epub 2017 Dec 8. PubMed PMID: 29227816. PMCID: PMC5777154.
Radiology focused.
169.
Hyman DM1, Piha-Paul SA2, Won H1, Rodon J3, Saura C3, Shapiro GI4, Juric D5, Quinn
DI6, Moreno V7, Doger B7, Mayer IA8, Boni V9, Calvo E9, Loi S10, Lockhart AC11, Erinjeri JP1,
Scaltriti M1, Ulaner GA1, Patel J1, Tang J1, Beer H1, Selcuklu SD1, Hanrahan AJ1, Bouvier N1,
Melcer M1, Murali R1, Schram AM1, Smyth LM1, Jhaveri K1, Li BT1, Drilon A1, Harding JJ1, Iyer
G1, Taylor BS1, Berger MF1, Cutler RE Jr12, Xu F12, Butturini A12, Eli LD12, Mann G12, Farrell
C12, Lalani AS12, Bryce RP12, Arteaga CL8, Meric-Bernstam F2, Baselga J1, Solit DB1. HER
kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018 Feb
8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.
170.
Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J,
Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D,
Blumenstein L, Coughlin C, Quadt C, Baselga J. “Phosphatidylinositol 3-Kinase α-Selective
Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-inHuman Study.” J Clin Oncol. 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. Epub
2018 Feb 5. PubMed PMID: 29401002. PMCID: PMC5920739.
171.
Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, GrisOliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P,
de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R,
Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin
A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O,
O'Connor MJ, Balmaña J, Serra V. “RAD51 foci as a functional biomarker of homologous
recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.” Ann
Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099. PubMed PMID: 29635390;
PubMed Central PMCID: PMC5961353. BASIC SCIENCE
172.
Dickler MN, Saura C, Richards D, Krop I, Cervantes A, Bedard PL, Patel MR, Pusztai L,
Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J. “Phase II Study
of Taselisib (GDC‑0032) in Combination with Fulvestrant in Patients with HER2-Negative,
Hormone Receptor-Positive Advanced Breast Cancer.” Clin Cancer Res. 2018 May 23. pii:
clincanres.0613.2018. doi: 10.1158/1078-0432.CCR-18-0613. [Epub ahead of print] PubMed PMID:
29793946. NIHMS ID: NIHMS972105
173.
Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L,
Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios
CH, Baselga J, Moreno-Aspitia A, Piccart M, Gelber RD, de Azambuja E. “Adjuvant Anti-HER2
Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early
Breast Cancer Patients.” J Natl Cancer Inst. 2018 Jun 5. doi: 10.1093/jnci/djy094. [Epub ahead of
print] PubMed PMID: 29878225. The main study was negative and this was a secondary study
endpoint. This agent was not developed for this indication.
174.
Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C,
Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva
AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J. “Phase 1/1b dose escalation and expansion
study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including
patients with advanced breast cancer.” Cancer Chemother Pharmacol. 2018 Jun 7. doi:
10.1007/s00280-018-3610-z. [Epub ahead of print] PubMed PMID: 29882016. NIHMS ID:

 NIHMS974436. PI3K inhibitor study conducted many years ago and the compound has not
been further developed
175.
Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, Solit DB,
Baselga J, Arcila ME, Ladanyi M, Zhang L, Levine RL, Berger MF, Zehir A. “Prevalence of Clonal
Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors.” JAMA
Oncol. 2018 Jun 5. doi: 10.1001/jamaoncol.2018.2297. [Epub ahead of print] PubMed PMID:
29872864. Edit Public Access Compliance StatusEdit Public Access Compliance Status NIH Public
Access Compliance: In process at NIHMS. [Edit Status] NIHMS ID: NIHMS973636. BASIC
SCIENCE
176.
Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de
Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L,
Hatzis C. “Association of T-Cell Receptor Repertoire Use With Response to Combined TrastuzumabLapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO
Randomized Clinical Trial.” JAMA Oncol. 2018 Jun 14:e181564. doi: 10.1001/jamaoncol.2018.1564.
[Epub ahead of print] PubMed PMID: 29902299. NIHMS ID: NIHMS975604
177.
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D,
Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ,
Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris
MG. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a
Phase II Basket Trial. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi:
10.1200/JCO.2018.77.9777. Epub 2018 Jul 10.
178.
Bielski, C. M., A. Zehir, A. V. Penson, M. T. A. Donoghue, W. Chatila, J. Armenia, M. T.
Chang, A. M. Schram, P. Jonsson, C. Bandlamudi, P. Razavi, G. Iyer, M. E. Robson, Z. K. Stadler,
N. Schultz, J. Baselga, D. B. Solit, D. M. Hyman, M. F. Berger and B. S. Taylor (2018). "Genome
doubling shapes the evolution and prognosis of advanced cancers." Nature Genetics 50(8): 11891195. BASIC SCIENCE.